Bevacizumab, a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), is approved for treatment of metastatic colorectal cancer, nonsquamous non-small-cell lung cancer, metastatic kidney cancer, and glioblastoma. To support clinical development of the potential bevacizumab biosimilar PF-06439535, nonclinical studies evaluated structural, functional, toxicological, and toxicokinetic similarity to bevacizumab sourced from the European Union (bevacizumab-EU) and United States (bevacizumab-US). Peptide mapping demonstrated the amino acid sequence of PF-06439535 was identical to bevacizumab-EU and bevacizumab-US. Biologic activity, measured via inhibition of VEGF-induced cell proliferation in human umbilical vein endothelial cells and binding to VEGF isoforms, was similar across the three drugs. In vivo similarity was demonstrated in cynomolgus monkeys administered intravenous PF-06439535 or bevacizumab-EU (0 or 10 mg/kg/dose twice weekly for 1 month; total of nine doses). Systemic exposure appeared similar and test article-related effects were limited to physeal dysplasia of the distal femur. The potential for non-target-mediated toxicity of PF-06439535 was evaluated in rats administered intravenous PF-06439535 (15 or 150 mg/kg/dose twice weekly for 15 days; total of five doses). Nonadverse higher liver weights and minimal sinusoidal cell hyperplasia were observed. Collectively, these studies demonstrated similarity of PF-06439535 to bevacizumab, supporting entry into clinical development.
Introduction
Vascular endothelial growth factor (VEGF) mRNA expression has been demonstrated in various cancers, including those of the gastrointestinal tract, lung, kidney, ovary, and brain (Ellis et al., 1998; Huang et al., 2005; Sowter et al., 1997; Tomisawa et al., 1999; Volm et al., 1997) . Bevacizumab is a recombinant humanized monoclonal antibody targeting VEGF (European Medicines Agency, 2009; Genentech Inc, 2004) . Bevacizumab binds VEGF and inhibits its activity, thereby blocking VEGF-induced angiogenesis and other downstream effects (Ferrara, 2004) .
Bevacizumab is approved for treatment of metastatic colorectal cancer, nonsquamous non-small-cell lung cancer, metastatic kidney cancer, and glioblastoma (European Medicines Agency, 2009; Genentech Inc, 2004) . In some countries, bevacizumab is also approved for treatment of cervical cancer, metastatic breast cancer, and advanced epithelial ovarian, fallopian tube, or primary peritoneal cancers (European Medicines Agency, 2009) .
A biosimilar is highly similar to a licensed or approved originator biotherapeutic (European Medicines Agency, 2014; US Food and Drug Administration, 2015; World Health Organization, 2009 ). Biotherapeutics, particularly monoclonal antibodies, consist of relatively large and complex molecules that are difficult to replicate exactly (World Health Organization, 2009) . Numerous international authorities, such as the European Medicines Agency, US Food and Drug Administration, Japan's Pharmaceuticals and Medical Devices Agency, and the World Health Organization, have developed guidance documents describing criteria for approval of biosimilars that require rigorous comparison against the originator product (European Medicines Agency, 2014; Japan Pharmaceutical and Medical Devices Agency, 2009; US Food and Drug Administration, 2015; World Health Organization, 2009 ). According to these guidelines, a stepwise approach is recommended for the development of biosimilars. This includes analytical comparisons for structural and functional similarity, followed by clinical studies to compare pharmacokinetics, pharmacodynamics, immunogenicity, and the efficacy and safety of the potential biosimilar versus the originator product (European Medicines Agency, 2014; US Food and Drug Administration, 2015; World Health Organization, 2009) .
Regulatory agencies may be moving away from requiring in vivo nonclinical studies because extensive in vitro physicochemical and biological characterization establishes the core of biosimilarity (van Aerts et al., 2014) . Due to the likelihood that in vivo animal studies would not identify new safety signals, discussions are ongoing between regulatory authorities and pharmaceutical companies to lessen or eliminate nonclinical animal studies, unless there is remaining uncertainty regarding biosimilarity following in vitro analytical studies (Chapman et al., 2016; O'Connor and Rogge, 2013; van Aerts et al., 2014; van Meer et al., 2015) .
PF-06439535 is under development as a proposed biosimilar to bevacizumab. The evaluation of PF-06439535 included several studies undertaken to compare structure, function, toxicity, and/or toxicokinetics (TK) to bevacizumab originator products sourced from the European Union (bevacizumab-EU) and the United States (bevacizumab-US). As part of the structural similarity assessment, it was necessary to confirm that the amino acid sequence of PF-06439535 is identical to that of the reference product. According to regulatory guidelines, the in vitro functional assays should be designed to demonstrate that the proposed biosimilar and the originator are similar with respect to characteristics representative of and based on the mechanism of action of the originator (US Food and Drug Administration, 2015) . Bevacizumab binds VEGF and prevents the interaction of VEGF with its receptors (Genentech Inc, 2004) . To assess whether PF-06439535 has the same mechanism of action as the originator, in vitro bioassays that included the inhibition of VEGF-induced cell proliferation and VEGF isoform binding were performed.
At the time the studies presented here were performed, guidance from international authorities recommended animal studies in a pharmacologically relevant species (i.e., a species in which the originator possesses pharmacodynamic and/or toxicologic activity), and designed to maximize the information obtained (World Health Organization, 2009 ). In addition, in some cases, a health authority may require a limited noncomparative study in a nonrelevant species to demonstrate safety (Chapman et al., 2016; Derzi et al., 2016) . Based on the high sequence similarity between human and cynomolgus monkey VEGF and evidence of pharmacology (i.e., physeal dysplasia of the distal femur secondary to angiogenesis inhibition in skeletally immature animals) in cynomolgus monkey toxicity studies (European Medicines Agency, 2009; Hoffmann-La Roche Ltd, 2015; US Food and Drug Administration, 2012) , the cynomolgus monkey was considered a suitable and pharmacologically relevant species for determining potential differences in toxicity and TK between PF-06439535 and bevacizumab. Therefore, a nonclinical in vivo study was conducted to compare toxicity and TK of PF-06439535 and bevacizumab-EU in young male cynomolgus monkeys.
Rats are a nonpharmacologically active species since bevacizumab does not bind endogenous rat VEGF . At the request of a regulatory agency, an additional study was conducted in male and female rats to assess the potential for non-target-mediated toxicity of PF-06439535.
Materials and methods

Structural and functional assays
For all structural and functional assays, PF-06439535 was compared with bevacizumab-EU and bevacizumab-US.
2.1.1. Peptide mapping using liquid chromatography/mass spectrometry Samples were reduced, alkylated, and digested with Lys-C. This was followed by reversed-phase high-performance liquid chromatography and ultra-high-resolution electrospray ionization quadruple time-of-flight mass spectrometry with ultraviolet absorbance monitored at 214 nm.
Cell growth assay
In vitro biologic activity of PF-06439535, bevacizumab-EU, and bevacizumab-US was compared via inhibition of VEGF-induced cell proliferation in human umbilical vein endothelial cells (HUVEC). HUVEC were incubated with a constant concentration of VEGF isoform 165 (VEGF 165 ) and varying concentrations of PF-06439535, bevacizumab-EU, or bevacizumab-US. Antiproliferative effects were assessed via luminescent measurement of adenosine triphosphate, which is proportional to the amount of metabolically active cells and proliferation.
VEGF isoform binding
Binding of PF-06439535, bevacizumab-EU, and bevacizumab-US to the major VEGF isoforms (VEGF 121 , VEGF 165 , VEGF 189 , and VEGF 206 ) was assessed by an enzyme-linked immunosorbent assay (ELISA). This ELISA uses microtiter plates coated with a VEGF isoform. Varying concentrations of PF-06439535, bevacizumab-EU, or bevacizumab-US were added and bound protein was detected using an enzyme-labeled goat antihuman immunoglobulin G antibody with a colorimetric substrate; optical density (proportional to the amount of bevacizumabbound VEGF) was measured spectrophotometrically.
In vivo studies
For the in vivo studies, two lots of PF-06439535 and of bevacizumab-EU were used. Studies were conducted in accordance with the current guidelines for animal welfare (National Research Council, 1996) .
In vivo monkey toxicity study
In vivo toxicity and TK were evaluated for similarity between PF-06439535 or bevacizumab-EU in skeletally immature male cynomolgus monkeys aged 2 years and 5 months to 3 years and 3 months at initiation of dosing. Monkeys (n = 4/group) were administered 10 mg/kg/dose PF-06439535 or bevacizumab-EU (twice weekly) on Days 1, 4, 8, 11, 15, 18, 22, 25, and 29 via intravenous (i.v.) injection, for a total of nine doses. Control animals received PF-06439535 vehicle or the bevacizumab-EU vehicle, which were slightly different from one another. The i.v. route of administration was selected because it is the intended route of bevacizumab administration in humans (European Medicines Agency, 2015; Genentech Inc, 2004) .
Assessment of toxicity was based on mortality, clinical observations, body weight, food consumption, ophthalmic examinations, electrocardiograms, respiration rate, and clinical and anatomic pathology (including weights of selected organs and microscopic examination of a full set of tissues). Blood samples were collected for TK assessments and antidrug antibody (ADA) analysis (see section 2.3). Necropsies were conducted on Day 32, 3 days after the last dose.
In vivo rat toxicity study
In vivo toxicity and TK of PF-06439535 were evaluated in male and female Sprague Dawley rats 7 to 8 weeks of age with body weights ranging from 226 to 302 g for males and 187 to 228 g for females at the initiation of dosing. Rats were administered vehicle or PF-06439535 at 15 or 150 mg/kg/ dose (twice weekly) on Days 1, 4, 8, 11, and 15 via i.v. injection, for a total of five doses.
Ten male and ten female rats from each group were allocated for evaluation of toxicity based on mortality, clinical observations, body weight, food consumption, ophthalmic examinations, and clinical and anatomic pathology (including weights of selected organs and on microscopic examination of a full set of tissues). Necropsies were conducted on Day 16, the day after the last dose. Three (control) or four (PF-06439535-dosed groups) rats/ sex from each group were allocated for evaluation of TK and ADA (see section 2.3). Serum samples were analyzed for PF-06439535 or bevacizumab-EU concentration using a single, validated ELISA. Samples were diluted in assay buffer and incubated on a microtiter plate coated with recombinant human VEGF. Bound PF-06439535 or bevacizumab-EU was detected by goat antihuman immunoglobulin G horseradish peroxidase. The addition of the enzyme substrate tetramethylbenzidine was used for signal generation and a colorimetric readout was completed on a microplate spectrophotometer at 450 nm. Serum concentrations of PF-06439535 or bevacizumab-EU were determined by interpolation from a standard curve that was fit using a fourparameter logistic regression model with a weighting factor of 1/Y. The range of quantitation in 100% cynomolgus monkey serum or Sprague Dawley rat serum was 10.0-400 μg/mL.
Determination of ADA in serum
Blood samples were collected from nonfasted animals for evaluation of serum ADA via venipuncture at single time points on Days 1, 15, and 25 in the monkey study, and Days 1 and 15 in the rat study. In the monkey study, ADA samples were collected from all animals, whereas in the rat study, samples were collected from animals assigned to TK/ADA evaluation. Two electrochemiluminescent immunoassays using the Meso Scale Discovery platform (MSD Inc., Rockville, MD) were validated for the detection of ADA to PF-06439535 or bevacizumab-EU in cynomolgus monkey serum (first assay) and to PF-06439535 in rat serum (second assay). In the validated assays, study samples, the positive control (affinity-purified rabbit anti-bevacizumab antibody), and negative control (pooled normal rat or cynomolgus monkey serum) were co-incubated with biotinylated PF-06439535 or biotinylated bevacizumab-EU and ruthenylated PF-06439535 or ruthenylated bevacizumab-EU. In this assay, antibodies to PF-06439535 or bevacizumab-EU must bind both the biotinylated and ruthenium-labeled PF-06439535 or bevacizumab-EU to be detected. Bound ADA was captured using streptavidincoated multi-array plates (MSD Inc). Ruthenium in the presence of tripropylamine buffer produced a chemiluminescent signal when voltage was applied; the resulting chemiluminescence was measured in response units on a Sector Imager 6000 instrument (MSD Inc).
Results
Structural and functional assays
The analytical similarity assessment consisted of testing over 50 lots of the reference product along with multiple lots of PF-06439535. Only representative data are presented below.
3.1.1. Peptide mapping using liquid chromatography/mass spectrometry Chromatographic profiles of PF-06439535 were superimposable with bevacizumab-EU and bevacizumab-US (Fig. 1) . The consistent peak-by-peak peptide identifications by mass spectrometry demonstrated all three products have the same primary amino acid sequence.
Cell growth assay
Functional bioassays showed that the relative potencies of PF-06439535, bevacizumab-EU, and bevacizumab-US were similar (Fig. 2) . The overlaid dose-response curves demonstrated similar inhibition of VEGF-induced activity. 
VEGF isoform binding
The binding of PF-06439535, bevacizumab-EU, and bevacizumab-US to VEGF isoforms was similar (Fig. 3) . The overlaid response curves demonstrate similarity of the three products in ability to bind to each of the human VEGF isoforms in a dose-dependent manner.
In vivo monkey toxicity study
Administration of PF-06439535 or bevacizumab-EU was well tolerated; all animals survived to their scheduled termination on Day 32. There were no PF-06439535-or bevacizumab-EU-related findings in clinical signs, body weight, food consumption, ophthalmology examinations, respiration rate, electrocardiograms, hematology, coagulation, clinical chemistry, or urinalysis parameters, and there were no PF-06439535-or bevacizumab-EU-related changes in organ weights, or necropsy findings. All animals were skeletally immature based on the presence of active (open) growth plates at the distal femur. PF-06439535-and bevacizumab-EU-related effects were limited to minimal to moderate physeal dysplasia observed in the growth plate of the distal femur in all animals administered either PF-06439535 or bevacizumab-EU; no physeal dysplasia was observed in animals administered either vehicle alone (Fig. 4) .
There were no biologically or toxicologically relevant differences in the incidence and severity of microscopic findings between PF-06439535-and bevacizumab-EU-administered groups (Table 1) . The physeal dysplasia in the distal femur observed with PF-06439535 and bevacizumab-EU administration was consistent with the expected pharmacologic effect of inhibition of blood vessel formation in growing bone and known responses to bevacizumab (European Medicines Agency, 2005) . This finding was considered adverse in animals with active growth plates.
Quantifiable concentrations of PF-06439535 or bevacizumab-EU from Day 1 through Day 30 confirmed exposure over the duration of the study. Systemic exposure, as assessed by mean maximum serum concentration (C max ) and area under the serum concentration-time curve (AUC) from time 0-72 h (AUC 0-72 ), on Days 1 and 25 appeared similar between PF-06439535-and bevacizumab-EU-dosed groups (Table 2) .
Exposure (AUC 0-72 ) on Day 25 was increased versus the exposure on Day 1 by 3.8 × for PF-06439535 and 3.1 × for bevacizumab-EU (Fig. 5) . TK parameter ratios (PF-06439535 to bevacizumab-EU) appeared similar and ranged from 0.8 to 1.0 (Table 2) . There was no incidence of ADA induction.
In vivo rat toxicity study
Administration of PF-06439535 was well tolerated. All animals survived to the scheduled termination on Day 16. PF-06439535 had no effects on clinical observations. Body weight gain for Days 8 through 15 and Days 1 through 16 was significantly higher in male rats administered 150 mg/kg/dose versus male rats administered vehicle. Specifically, body weight gain in PF-06439395-administered male rats was 1.5 × mean control value between Days 1 through 16 (p = 0.0041) and 1.4 × mean control value between Days 8 and 15 (p = 0.0046; Table 3 ). This resulted in higher (1.1 × ) mean terminal body weight in males administered PF-06439535 versus males administered vehicle. PF-06439535 had no effect on body weight in any female group. PF-06439535 also had no effect on body weight or body weight change in the animals used in the TK/ADA analyses.
The only PF-06439535-related microscopic finding was minimal sinusoidal cell hyperplasia, characterized by an increase in number and/or size (i.e., hypertrophy) of cells that often had faintly basophilic cytoplasm in the liver of male and female rats administered 150 mg/kg/ 
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Regulatory Toxicology and Pharmacology 95 (2018) 236-243 dose (Table 4 ). This correlated with higher absolute (1.25 × ), relative to body (1.14 × ), and relative to brain (1.31 × ) mean liver weights in males receiving 150 mg/kg/dose, compared with the control male group (p ≤ 0.05). In female rats, sinusoidal cell hyperplasia occurred at a lower incidence compared with males (Table 4) . This may explain why there were no PF-06439535-related liver weight changes observed at 150 mg/kg/dose. Systemic exposure, as assessed by C max and AUC 0-72 , was similar between male and female rats. Mean systemic exposure increased with dose in a slightly less than dose-proportional manner on Days 1 and 11 (Table 5 ). Based on mean AUC 0-72 values, the mean accumulation ratios (AUC 0-72 , Day 11 to Day 1) ranged from 2.3 to 2.6 in males and 2.7 to 3.0 in females. There was no incidence of ADA induction.
Discussion
This nonclinical program compared the structure and function of the potential bevacizumab biosimilar PF-06439535 to the originator products bevacizumab-EU and bevacizumab-US. Additionally, in vivo toxicity and TK were compared between PF-06439535 and bevacizumab-EU in skeletally immature male cynomolgus monkeys and toxicity and TK of PF-06439535 were evaluated in male and female Sprague Dawley rats.
Overall, the results of the in vitro analytical assessments indicated PF-06439535 was similar to bevacizumab-EU and/or bevacizumab-US. Peptide mapping confirmed PF-06439535 has an identical primary amino acid sequence as bevacizumab-EU and bevacizumab-US. The overlaid HUVEC cell growth inhibition dose-response curves demonstrated functional similarity of PF-06439535, bevacizumab-EU, and bevacizumab-US. In addition, the overlaid VEGF target-binding doseresponse curves demonstrated similar ability of PF-06439535, bevacizumab-EU, and bevacizumab-US to bind multiple VEGF isoforms. These data support the conclusion that PF-06439535 is similar to both bevacizumab-EU and bevacizumab-US with respect to sequence, binding, and functional effects. 
a Administered PF-06439535 vehicle. b Administered bevacizumab vehicle.
Table 2
Mean ( ± SD) toxicokinetic parameters for PF-06439535 and bevacizumab-EU and ratio for PF-06439535 relative to bevacizumab-EU in male cynomolgus monkeys following twice-weekly intravenous administration for 1 month (total of nine doses). . Mean ( ± SD) serum concentration vs time profiles in cynomolgus monkeys administered PF-06439535 and bevacizumab-EU intravenously at doses of 10 mg/kg/dose twice weekly for 1 month (total of nine doses). SD = standard deviation.
Table 3
Summary of body weight change (mean ± SD) of Sprague Dawley rats (n = 10/group/sex) administered PF-06439535 (15 or 150 mg/kg/dose) or vehicle (0 mg/kg/ dose) twice weekly.
Males Females
Mean ± SD body weight change (g) 0 mg/kg 15 mg/kg 150 mg/kg 0 mg/kg 15 mg/kg 150 mg/kg Days 1 through 8 41 ± 9.9 47 ± 11.8 52 ± 11.2 17 ± 4.8 18 ± 4.4 14 ± 3.9 Days 8 through 15 32 ± 6.7 37 ± 7.4 44 ± 9.1 a 9 ± 4.4 13 ± 6.7 9 ± 3.4 Days 15 through 16 −28 ± 6.3 −28 ± 4.4 −26 ± 4.9 −19 ± 3.4 −18 ± 5.0 −16 ± 3.9 Days 1 through 16 46 ± 15.1 56 ± 16.7 70 ± 16.6 a 7 ± 8.2 13 ± 6.1 7 ± 6.1 a p ≤ 0.05 versus vehicle. SD = standard deviation.
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Regulatory Toxicology and Pharmacology 95 (2018) 236-243 The role of nonclinical in vivo toxicity studies in biosimilar development is evolving. Nonclinical animal studies may be needed only if there is residual uncertainty regarding biosimilarity following in vitro analytical studies (Chapman et al., 2016; O'Connor and Rogge, 2013; van Aerts et al., 2014; van Meer et al., 2015) . However in 2013, at the time of initiation of the current studies described here, guidance and feedback from regulatory agencies indicated that a nonclinical in vivo study was warranted. Therefore, toxicity of PF-06439535 and bevacizumab-EU was evaluated using the pharmacologically-relevant species, cynomolgus monkeys. PF-06439535 and bevacizumab-EU were well tolerated in skeletally-immature male animals. Serum concentrations of PF-06439535 and bevacizumab-EU accumulated over the course of the study, and systemic exposure appeared similar between the two molecules. TK parameter ratios (PF-06439535: bevacizumab-EU) also appeared similar.
The only noted effects related to PF-06439535 or bevacizumab-EU in monkeys were microscopic observations of physeal dysplasia in the distal femur. The incidence and severity of the physeal dysplasia appeared similar between PF-06439535 and bevacizumab-EU. Although this finding is considered adverse in animals with active growth plates, it is consistent with the expected pharmacologic effect of inhibition of blood vessel formation in growing bone (Ryan et al., 1999) . This finding is also consistent with the previously described pharmacologic activity of bevacizumab on the physis of a growing bone (European Medicines Agency, 2005) . The TK data support that the physeal dysplasia occurred at similar exposures of PF-06439535 and bevacizumab-EU.
Although the rat is a standard rodent species used in toxicity studies, it is considered a nonpharmacologically active species for bevacizumab because bevacizumab does not bind endogenous rat VEGF . The rat study was undertaken at the request of a regulatory agency to assess the potential for nonpharmacologically-mediated toxicity of PF-06439535 in male and female animals. Twiceweekly i.v. administration of PF-06439535 in male and female rats was well tolerated. Systemic exposure to PF-06439535 appeared similar between male and female rats across doses. PF-06439535 at 150 mg/ kg/dose was associated with higher body weight gain and, consequently, higher terminal body weight than vehicle in male rats. The higher body weight was not considered adverse because of the small magnitude, lack of any other correlating findings, and the fact that the body weight was within the historical control range for this strain at this age (Charles River Labs, 2009 ).
PF-06439535-related minimal sinusoidal cell hyperplasia was seen in the livers of males and females administered 150 mg/kg/dose. PF-06439535-related higher mean absolute and relative liver weights were present in the male group administered 150 mg/kg/dose and correlated with the microscopic finding of minimal sinusoidal cell hyperplasia. Higher liver weights were not observed in the female group administered 150 mg/kg/dose, likely due to the lower incidence of the same finding in females. Higher liver weights were not considered adverse because of the relatively low magnitude of the change, the lack of correlating liver-specific clinical pathology findings, and the absence of clinically observed detrimental effects on the health of the animals. The microscopic finding of minimal sinusoidal cell hyperplasia in the liver of both sexes may be the result of a response to administration of foreign protein in a nonpharmacologically relevant species. The response could not be compared to the originator since the study was not designed to be comparative and there are no available data on the effects of the originator product in rats. The findings are likely related to an immune response since this has been observed previously in rodents administered the monoclonal antibody therapeutic, infliximab (Derzi et al., 2016; European Medicines Agency, 2013) . Although ADA were not detected in this study, the presence of high drug concentrations could have interfered with the detection of ADA. Individual animal PF-06439535 concentrations at the time of ADA assessment on Day 15 were ≥1770 μg/mL (data not shown), which was well above the drug tolerance limit of 200 μg/mL in the presence of 6000 ng/mL of the positive control ADA or 12.5 μg/mL in the presence of 200 ng/mL of the positive control ADA, which were established during assay validation. Although immunogenicity is a key attribute for establishing biosimilarity between the proposed biosimilar and the originator product, immunogenicity in animals is not predictive for humans (Bugelski and Treacy, 2004; van Meer et al., 2013) . Immunogenicity of PF-06439535 was/is monitored in completed and ongoing clinical studies (ClinicalTrials.gov identifiers: NCT02031991 and NCT02364999).
Overall, the findings in the monkey study comparing PF-06439535 and bevacizumab-EU, and the findings in the rat study evaluating PF-06439535 alone, were of very limited value in the assessment of Table 5 Mean ( ± SD) toxicokinetic parameters for PF-06439535 in Sprague Dawley rats on Days 1 and 11 after twice-weekly intravenous administration of PF-06439535 (n = 4 animals/sex/dose group).
biosimilarity, and we believe that the assessment of similarity of PF-06439535 with bevacizumab could have been based on the various in vitro analytical assessments without these in vivo studies. The finding that there were no relevant differences between PF-06439535 and bevacizumab-EU in the comparative study in monkeys is in agreement with the results from a review of European Public Assessment Reports for nine distinct biosimilarity exercises (van Meer et al., 2015) , and with the survey results evaluating 25 biosimilar programs (Chapman et al., 2016) , both of which noted that no relevant in vivo differences were detected between proposed biosimilars and the reference products, across a variety of programs. This is also consistent with the lack of relevant differences reported in in vivo pharmacokinetic and/or toxicity studies comparing the reference product with proposed biosimilars to rituximab , trastuzumab (Hurst et al., 2014) , and infliximab (Derzi et al., 2016) . In addition to the comparative study in monkeys, a noncomparative study in rats evaluating PF-06439535 was conducted at the request of a regulatory agency. The findings in the rat (a non-pharmacologically relevant species) also did not add value to the assessment of similarity. Thus, the findings from our in vivo nonclinical studies support the suggestion that animal studies provide limited value when there is a strong in vitro analytical package demonstrating similarity and support existing recommendations to reduce or eliminate animal use in assessment of biosimilars (Chapman et al., 2016; O'Connor and Rogge, 2013; van Aerts et al., 2014; van Meer et al., 2015) .
In conclusion, structural and functional assays demonstrate the overall similarity of PF-06439535 with bevacizumab-EU and bevacizumab-US. PF-06439535 and bevacizumab-EU had similar findings and systemic exposure in a repeat-dose toxicity study in cynomolgus monkeys, a pharmacologically relevant species. These studies supported the clinical development of PF-06439535; however, the in vivo studies in monkeys and rats added limited value, and the assessment of similarity could have been made using only in vitro analytical assessments.
Supplementary data related to this article can be found at http://dx. doi.org/10.1016/j.yrtph.2018.03.020.
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